TY - JOUR
T1 - Are we ready to use TMB in breast cancer clinical practice?
AU - Ravaioli, Sara
AU - Limarzi, Francesco
AU - Tumedei, Maria Maddalena
AU - Palleschi, Michela
AU - Maltoni, Roberta
AU - Bravaccini, Sara
N1 - Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - We discussed the potentialities of tumor mutation burden (TMB) as a predictive marker for immunotherapy in breast cancer, also highlighting the limits that have hindered its introduction in the clinical practice. Although some studies have demonstrated the possibility to select patients more responsive to immune-checkpoint inhibitors by evaluating TMB, some issues emerged regarding the complexity of the methodologies for its determination, the costs of the analysis, and the necessity to improve the TMB determination with that of neoantigen identification.
AB - We discussed the potentialities of tumor mutation burden (TMB) as a predictive marker for immunotherapy in breast cancer, also highlighting the limits that have hindered its introduction in the clinical practice. Although some studies have demonstrated the possibility to select patients more responsive to immune-checkpoint inhibitors by evaluating TMB, some issues emerged regarding the complexity of the methodologies for its determination, the costs of the analysis, and the necessity to improve the TMB determination with that of neoantigen identification.
KW - Breast cancer
KW - Immune-checkpoint inhibitors
KW - PD-L1
KW - TMB
UR - http://www.scopus.com/inward/record.url?scp=85088586586&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088586586&partnerID=8YFLogxK
U2 - 10.1007/s00262-020-02682-w
DO - 10.1007/s00262-020-02682-w
M3 - Editorial
C2 - 32725361
AN - SCOPUS:85088586586
VL - 69
SP - 1943
EP - 1945
JO - Cancer Immunology and Immunotherapy
JF - Cancer Immunology and Immunotherapy
SN - 0340-7004
IS - 10
ER -